Page 1001 - Hematology_ Basic Principles and Practice ( PDFDrive )

884 Part VII Hematologic Malignancies

a single malignancy, an evidence-based choice will be more difficult treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol
to make in the absence of head-to-head comparison in clinical trials. 27:3822, 2009. [Epub 2009 Jul 6]. PubMed PMID: 19581539.
In addition, a major question remains whether the newer signaling 10. Mascarenhas J, Hoffman R: Ruxolitinib: the first FDA approved therapy
inhibitors, “third-wave” agents, and newer immunotherapies only for the treatment of myelofibrosis. Clin Cancer Res 2012. [Epub ahead
achieve disease control and potentially prolong survival, without of print]. PubMed PMID: 22474318.
definitive disease eradication and cure. It is possible that the former 11. Harrison C, Kiladjian JJ, Al-Ali HK, et al: JAK inhibition with rux-
objective is sufficient for approaching normal lifespan in certain olitinib versus best available therapy for myelofibrosis. N Engl J Med
disorders, particularly those of indolent nature affecting patients of 366:787, 2012. PubMed PMID: 22375970.
more advanced age. However, aggressive disorders that represent a 11a. Friedberg JW, Vose JM, Kelly JL, et al: The combination of benda-
life-threatening condition when relapsed would be better treated mustine, bortezomib, and rituximab for patients with relapsed/
with curative intent. Strategies for aggressive, resistant, or relapsed refractory indolent and mantle cell non-Hodgkin lymphoma. Blood
disease will likely require inclusion of multiple agents of different 17(10):2807–2812, 2011.
generations and mechanisms of action. Current clinical trials are 12. Roberts AW, Seymour JF, Brown JR, et al: Substantial susceptibility of
exploring the use of combinations of signaling inhibitors or anti- chronic lymphocytic leukemia to BCL2 inhibition: results of a phase
apoptotic agents with “traditional” chemotherapeutic agents. These I study of navitoclax in patients with relapsed or refractory disease.
combinations, along with the addition of monoclonal antibody and J Clin Oncol 30:488, 2012. [Epub 2011 Dec 19]. PubMed PMID:
antibody–drug conjugate-based therapies as well as future strategies 22184378.
may achieve sufficient disease control to achieve disease eradication 13. Tong WG, Chen R, Plunkett W, et al: Phase I and pharmacologic study
and cure in a larger number of patients. Researchers and clinicians of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients
will need to also take into account the cost of these therapies and their with advanced chronic lymphocytic leukemia and multiple myeloma.
impact on quality of life, particularly as several target-based agents J Clin Oncol 28:3015, 2010. [Epub 2010 May 17]. PubMed PMID:
have been demonstrated to have activity as maintenance therapies. 20479412.
The long-term effects of many of these agents are still unknown. 14. Chen R, Wierda WG, Chubb S, et al: Mechanism of action of SNS-
Future clinical trial design and planning should include answers to 032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic
these questions: potential for cure versus disease control, rational leukemia. Blood 113:4637, 2009. [Epub 2009 Feb 20]. PubMed PMID:
use strategies, and identification of the most effective and least toxic 19234140; PubMed Central PMCID: PMC2680368.
therapeutic approaches for each disease. 14a. Wijermans PW, Krulder JW, Huijgens PC, et al: Continuous infusion
Certainly future considerations include the incorporation of of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk
genetic and genomic information into the clinic, as well as other myelodysplastic syndrome. Leukemia 11(Suppl 1):S19–S23, 1997.
markers of abnormalities of the “signalome” of a specific hematologic 14b. Kantarjian H, Oki Y, Garcia-Manero G, et al: Results of a randomized
malignancy. Application of these diagnostic strategies to a specific study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic
patient will allow for individual tailoring of the treatment strategy, syndrome and chronic myelomonocytic leukemia. Blood 109(1):52–57,
both based on the characteristics of the tumor and the individual 2007.
capacity to tolerate and metabolize drugs. Extensive validation studies 14c. de Lima M, Giralt S, Thall PF, et al: Maintenance therapy with low-
will be necessary to understand the true value of these tests in the dose azacitidine after allogeneic hematopoietic stem cell transplantation
management of patients with hematologic malignancies. for recurrent acute myelogenous leukemia or myelodysplastic syndrome:
a dose and schedule finding study. Cancer 116(23):5420–5431,
2010.
REFERENCES 15. Ellis L, Pan Y, Smyth GK, et al: Histone deacetylase inhibitor pano-
binostat induces clinical responses with associated alterations in gene
1. LoRusso PM, Boerner SA, Seymour L: An overview of the optimal expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res
planning, design, and conduct of phase I studies of new therapeutics. 14:4500, 2008. PubMed PMID: 18628465.
Clin Cancer Res 16:1710, 2010. [Epub 2010 Mar 9]. Review. PubMed 16. Younes A, Sureda A, Ben-Yehuda D, et al: Panobinostat in patients
PMID: 20215546. with relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell
2. Seymour L, Ivy SP, Sargent D, et al: The design of phase II clinical trials transplantation: results of a phase II study. J Clin Oncol 2012. [Epub
testing cancer therapeutics: consensus recommendations from the clinical ahead of print]. PubMed PMID: 22547596.
trial design task force of the National Cancer Institute Investigational 17. Richardson PG, Hungria VT, Yoon SS, et al: Panobinostat plus bort-
Drug Steering Committee. Clin Cancer Res 16:1764, 2010. [Epub ezomib and dexamethasone in previously treated multiple myeloma:
2010 Mar 9]. PubMed PMID: 20215557; PubMed Central PMCID: outcomes by prior treatment. Blood 127(6):713–721, 2016.
PMC2840069. 18. Mo W, Zhang JT: Human ABCG2: structure, function, and its role
3. Cheson BD, Rummel MJ: Bendamustine: rebirth of an old drug. J Clin in multidrug resistance. Int J Biochem Mol Biol 3:1, 2012. [Epub 2011
Oncol 27:1492, 2009. [Epub 2009 Feb 17]. Mar 30]; PubMed PMID: 22509477; PubMed Central PMCID:
4. Dobbelstein M, Moll U: Targeting tumour-supportive cellular machiner- PMC3325772.
ies in anticancer drug development. Nat Rev Drug Discov 13:179–196, 19. Tiwari AK, Sodani K, Wang SR, et al: Nilotinib (AMN107, Tasigna)
2014. reverses multidrug resistance by inhibiting the activity of the ABCB1/
5. Mohamed AJ, Yu L, Bäckesjö CM, et al: Bruton’s tyrosine kinase (Btk): Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol 78:153,
function, regulation, and transformation with special emphasis on the 2009. [Epub 2009 Apr 11]. PubMed PMID: 19427995.
PH domain. Immunol Rev 228:58, 2009. Review. PubMed PMID: 20. Karran P, Macpherson P, Ceccotti S, et al: O6-methylguanine residues
19290921. elicit DNA repair synthesis by human cell extracts. J Biol Chem
6. So L, Fruman DA: PI3K signalling in B- and T-lymphocytes: new devel- 268(21):15878–15886, 1993. PubMed PMID: 8340413.
opments and therapeutic advances. Biochem J 442:465, 2012. PubMed 21. Sancar A, Lindsey-Boltz LA, Unsal-Kaçmaz K, et al: Molecular mecha-
PMID: 22364281. nisms of mammalian DNA repair and the DNA damage checkpoints.
7. Zaytseva YY, Valentino JD, Gulhati P, et al: mTOR inhibitors in cancer Annu Rev Biochem 73:39–85, 2004. Review. PubMed PMID: 15189136.
therapy. Cancer Lett 319:1, 2012. [Epub 2012 Jan 17]. Review. PubMed 22. Egorin MJ, Van Echo DA, Tipping SJ, et al: Pharmacokinetics and
PMID: 22261336. dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)plati-
8. Liu Q, Thoreen C, Wang J, et al: mTOR mediated anti-cancer drug num in patients with impaired renal function. Cancer Res 44:5432–5438,
discovery. Drug Discov Today Ther Strateg 6:47, 2009. PubMed PMID: 1984.
20622997; PubMed Central PMCID: PMC2901551. 23. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage:
9. Hess G, Herbrecht R, Romaguera J, et al: Phase III study to evalu- prospective evaluation of a simple formula based on renal function. J
ate temsirolimus compared with investigator’s choice therapy for the Clin Oncol 7:1748–1756, 1989.